Agios Pharmaceuticals (AGIO) Receivables - Other (2013 - 2026)

Agios Pharmaceuticals' Receivables - Other history runs 14 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• Quarterly Receivables - Other rose 382.42% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (up 382.42% YoY) and the FY2025 annual result came in at $10.6 million, up 157.41% from the prior year.
• Receivables - Other was $16.1 million for Q1 2026 at Agios Pharmaceuticals, up from $10.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $16.1 million in Q1 2026 and bottomed at $987000.0 in Q1 2022.
• A 5-year average of $4.2 million and a median of $3.3 million in 2025 frame the typical range for Receivables - Other.
• Peak annual rise in Receivables - Other reached 430.76% in 2022, while the deepest fall reached 80.35% in 2022.
• Agios Pharmaceuticals' Receivables - Other stood at $2.2 million in 2022, then gained by 27.38% to $2.8 million in 2023, then soared by 46.23% to $4.1 million in 2024, then soared by 157.41% to $10.6 million in 2025, then surged by 52.52% to $16.1 million in 2026.
• Business Quant data shows AGIO's Receivables - Other at $16.1 million in Q1 2026, $10.6 million in Q4 2025, and $5.0 million in Q3 2025.